EPIX
ESSA Pharma Inc · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website essapharma.com
- Employees(FY) 50
- ISIN CA29668H7085
Performance
-6.99%
1W
-71.55%
1M
-67.42%
3M
-69.65%
6M
-73.79%
YTD
-67.96%
1Y
Profile
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Technical Analysis of EPIX 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-03 19:14
- 2024-10-31 20:14
- 2024-10-31 08:57
- 2024-09-14 09:53
- 2024-09-13 05:19
- 2024-09-11 04:05
- 2024-08-04 19:03
ESSA Pharma: Fiscal Q3 Earnings Snapshot(Yahoo Finance)
- 2024-08-04 19:00
- 2024-07-08 04:05
- 2024-05-29 20:00
- 2024-05-19 19:36
- 2024-05-14 01:54
EPIX Stock Earnings: ESSA Pharma Misses EPS for Q2 2024(Investorplace)
- 2024-05-13 19:04
ESSA Pharma: Fiscal Q2 Earnings Snapshot(Yahoo Finance)
- 2024-05-13 19:00
- 2024-04-08 20:00
- 2024-03-07 07:13
- 2024-02-26 00:14
12 $10 Stocks That Will Triple(Yahoo Finance)
- 2024-02-13 15:35
- 2024-02-12 18:25
ESSA Pharma: Fiscal Q1 Earnings Snapshot(Yahoo Finance)
- 2024-02-12 18:00
- 2024-02-07 20:47
ESSA Pharma Inc Executive Peter Virsik Sells 72,782 Shares(GuruFocus.com)
- 2024-02-06 08:00
- 2024-02-05 19:00
- 2024-01-26 05:36
EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…(Zacks Small Cap Research)
- 2024-01-25 10:00
- 2024-01-22 07:16
- 2023-12-21 16:13
These Stocks under $10 Are Poised To Explode(Insider Monkey)
- 2023-12-20 08:23
EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…(Zacks Small Cap Research)
- 2023-12-12 09:12
- 2023-12-12 07:20
ESSA Pharma: Fiscal Q4 Earnings Snapshot(Associated Press Finance)
Page 1 of 4
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.